1
|
Labonia MCI, Estapé Senti M, van der Kraak PH, Brans MAD, Dokter I, Streef TJ, Smits AM, Deshantri AK, de Jager SCA, Schiffelers RM, Sluijter JPG, Vader P. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration. J Control Release 2024; 369:734-745. [PMID: 38604385 DOI: 10.1016/j.jconrel.2024.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 04/05/2024] [Accepted: 04/08/2024] [Indexed: 04/13/2024]
Abstract
Despite research efforts being made towards preserving (or even regenerating) heart tissue after an ischemic event, there is a lack of resources in current clinical treatment modalities for patients with acute myocardial infarction that specifically address cardiac tissue impairment. Modified messenger RNA (modRNA) presents compelling properties that could allow new therapeutic strategies to tackle the underlying molecular pathways that ultimately lead to development of chronic heart failure. However, clinical application of modRNA for the heart is challenged by the lack of effective and safe delivery systems. Lipid nanoparticles (LNPs) represent a well characterized class of RNA delivery systems, which were recently approved for clinical usage in mRNA-based COVID-19 vaccines. In this study, we evaluated the potential of LNPs for cardiac delivery of modRNA. We tested how variations in C12-200 modRNA-LNP composition affect transfection levels and biodistribution after intramyocardial administration in both healthy and myocardial-infarcted mice, and determined the targeted cardiac cell types. Our data revealed that LNP-mediated modRNA delivery outperforms the current state of the art (modRNA in citrate buffer) upon intramyocardial administration in mice, with only minor differences among the formulations tested. Furthermore, we determined both in vitro and in vivo that the cardiac cells targeted by modRNA-LNPs include fibroblasts, endothelial cells and epicardial cells, suggesting that these cell types could represent targets for therapeutic interference with these LNP formulations. These outcomes may serve as a starting point for LNP development specifically for therapeutic mRNA cardiac delivery applications.
Collapse
Affiliation(s)
- M C I Labonia
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | - M Estapé Senti
- Laboratory of CDL Research, UMC, Utrecht, the Netherlands
| | - P H van der Kraak
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | - M A D Brans
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | - I Dokter
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | - T J Streef
- Department of Cell and Chemical Biology, Leiden University Medical Center, the Netherlands
| | - A M Smits
- Department of Cell and Chemical Biology, Leiden University Medical Center, the Netherlands
| | - A K Deshantri
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | - S C A de Jager
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands
| | | | - J P G Sluijter
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands; UMC Utrecht Regenerative Medicine Center, Circulatory Health Research Center, University Medical Center Utrecht, Utrecht University, Utrecht 3508GA, the Netherlands
| | - P Vader
- Department of Cardiology, Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands; Laboratory of CDL Research, UMC, Utrecht, the Netherlands.
| |
Collapse
|
2
|
van Kammen CM, van Woudenberg SJ, Schiffelers R, Terstappen F, Lely AT. Nanomedicines: An approach to treat placental insufficiency and the current challenges. J Control Release 2023; 360:57-68. [PMID: 37330012 DOI: 10.1016/j.jconrel.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/16/2023] [Accepted: 06/02/2023] [Indexed: 06/19/2023]
Abstract
INTRODUCTION Preeclampsia and fetal growth restriction are common pregnancy complications that significantly impact perinatal health and offspring development later in life. The origin of these complex syndromes overlap in placental insufficiency. Progress in developing treatments for maternal, placental or fetal health is mainly limited by the risk of maternal and fetal toxicity. Nanomedicines are a promising approach to safely treat pregnancy complications since they can regulate drug interaction with the placenta to enhance efficacy of the treatment while minimizing exposure of the fetus. METHODS This narrative review discusses the current developments and challenges of nanomedicines during pregnancy with a focus on preclinical models of placenta insufficiency syndromes. Firstly, we outline the safety requirements and potential therapeutic maternal and placental targets. Secondly, we review the prenatal therapeutic effects of the nanomedicines that have been tested in experimental models of placental insufficiency syndromes. RESULTS The majority of liposomes and polymeric drug delivery system show promising results regarding the prevention of trans-placental passage nanomedicines in uncomplicated and complicated pregnancies. The others two studied classes, quantum dots and silicon nanoparticles, have been investigated to a limited extent in placental insufficiency syndromes. Characteristics of the nanoparticles such as charge, size, and timing of administration have been shown to influence the trans-placental passage. The few available preclinical therapeutic studies on placental insufficiency syndromes predominantly show beneficial effects of nanomedicines on both maternal and fetal health, but demonstrate contradicting results on placental health. Interpretation of results in this field is complicated by the fact that results are influenced by the choice of animal species and model, gestational age, placental maturity and integrity, and nanoparticle administration route. CONCLUSION Nanomedicines form a promising therapeutic approach during (complicated) pregnancies mainly by reducing fetal toxicity and regulating drug interaction with the placenta. Different nanomedicines have been proven to effectively prevent trans-placental passage of encapsulated agents. This can be expected to dramatically reduce risks for fetal adverse effects. Furthermore, a number of these nanomedicines positively impacted maternal and fetal health in animal models for placental insufficiency. Demonstrating that effective drug concentrations can be reached in the target tissue. While these first animal studies are encouraging, more research is needed to better understand the influence of the pathophysiology of this multi-factorial disease before implementation in clinical practice can be considered. Therefore, extensive evaluation of safety and efficacy of these targeted nanoparticles is needed within multiple animal, in vitro, and/or ex vivo models. This may be complemented by diagnostic tools to assess the disease status to identify the best time to initiate treatment. Together these investigations should contribute to building confidence in the safety of nanomedicines for treating mother and child, as safety has, understandably, the highest priority in this sensitive patient groups.
Collapse
Affiliation(s)
- C M van Kammen
- University Medical Center Utrecht, Department CDL research, Nano medicine, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
| | - S J van Woudenberg
- University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Woman and Baby, Lundlaan 6, 3584 EA Utrecht, the Netherlands
| | - R Schiffelers
- University Medical Center Utrecht, Department CDL research, Nano medicine, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands
| | - F Terstappen
- University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Woman and Baby, Lundlaan 6, 3584 EA Utrecht, the Netherlands
| | - A T Lely
- University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Woman and Baby, Lundlaan 6, 3584 EA Utrecht, the Netherlands
| |
Collapse
|
3
|
Fang J, Van Der Geest JSA, Yao B, Yang Q, Chirico N, Brans MA, Roefs MT, Vader P, De Jager SCA, De Bruin A, Vink A, Van Mil A, Schiffelers RM, Lei Z, Sluijter JPG. E2F7/8 is involved in cardiomyocyte polyploidy but does not affect myocardial reperfusion injury recovery. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Other. Main funding source(s): CSC fellowship
Background
Polyploidy cells consist of more than two complete sets of homologous chromosomes. Although a characteristic feature of cardiomyocytes and observed in all mammalian species, its molecular mechanism and biological functions are still unknown. Cardiomyocytes polyploidy in rodents occurs mainly through incomplete cytokinesis and increases with age. Studies have demonstrated that E2F7/8 transcription factors are key regulators of polyploidy in the liver and pancreas, however, it remains unclear if E2F7/8 control the generation of polyploidy cardiomyocytes and what the functional consequence is post-myocardial infarction (MI).
Methods
By using a tamoxifen inducible Cre/LoxP approach in new-born mice, we deleted E2F7/8 transcription factors ubiquitously and evaluated the biological significance of postnatal E2F7/8 loss. Mice underwent myocardial ischemia reperfusion injury (IRI) and heart function was assessed by 4D-echocardiography. Cardiomyocyte nucleus polyploidy was measured by FACS and microscope.
Results
Deficiency of E2F7/8 significantly suppress cardiomyocyte mononucleated and multinucleated polyploidy, as well as dramatically decreased hepatocytes polyploidy. E2F7/8 defect also led to a decrease in cardiac stress related marker lever such as ANP, BNP, MMP2, β-MHC/α-MHC and an increase in CD31 expression level. Surprisingly, E2F7/8 deletion did not have impact on cardiac function and dimensions post-IRI.
Conclusion
In summary, we identified that E2F7/8 activity is involved in the cellular polyploidy in the heart but did not affect myocardial function after myocardial injury.
Collapse
Affiliation(s)
- J Fang
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - JSA Van Der Geest
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - B Yao
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - Q Yang
- University Medical Center Utrecht, CDL Research , Utrecht , Netherlands (The)
| | - N Chirico
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - MA Brans
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - MT Roefs
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - P Vader
- University Medical Center Utrecht, Experimental Cardiology and CDL Research , Utrecht , Netherlands (The)
| | - SCA De Jager
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - A De Bruin
- University of Groningen, Department of Pediatrics , Groningen , Netherlands (The)
| | - A Vink
- University Medical Center Utrecht, Department of Pathology , Utrecht , Netherlands (The)
| | - A Van Mil
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| | - RM Schiffelers
- University Medical Center Utrecht, CDL Research , Utrecht , Netherlands (The)
| | - Z Lei
- University Medical Center Utrecht, Experimental Cardiology and CDL Research , Utrecht , Netherlands (The)
| | - JPG Sluijter
- University Medical Center Utrecht, Experimental Cardiology , Utrecht , Netherlands (The)
| |
Collapse
|
4
|
Swart L, Derevyanko P, van Oort A, Ashtiani M, Krippner-Heidenreich A, Koekman A, Seinen C, Issa H, Blair H, Schiffelers R, Heidenreich O. P465: A LIPID NANOPARTICLE DELIVERY SYSTEM FOR TARGETING THE LEUKAEMIC FUSION GENE RUNX1/ETO BY SIRNA. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844748.73548.4f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Swart L, van Oort A, Ashtiani M, Krippner-Heidenreich A, Kooijmans S, Tuk D, Koekman A, Seinen C, Issa H, Blair H, Schiffelers R, Heidenreich O. Silencing the leukaemic fusion gene RUNX1/ETO by siRNA-loaded
lipid nanoparticles restores myeloid differentiation. KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L Swart
- Princess Maxima Centrum for Pediatric Oncology, Utrecht, The
Netherlands
| | - A van Oort
- Princess Maxima Centrum for Pediatric Oncology, Utrecht, The
Netherlands
| | - M Ashtiani
- Princess Maxima Centrum for Pediatric Oncology, Utrecht, The
Netherlands
| | | | - S Kooijmans
- Clinical Chemistry and Haematology, University Medical Center Utrecht,
Heidelberglaan 100, Utrecht 3584 CX, The Netherlands
| | - D Tuk
- Princess Maxima Centrum for Pediatric Oncology, Utrecht, The
Netherlands
| | - A Koekman
- Clinical Chemistry and Haematology, University Medical Center Utrecht,
Heidelberglaan 100, Utrecht 3584 CX, The Netherlands
| | - C Seinen
- Clinical Chemistry and Haematology, University Medical Center Utrecht,
Heidelberglaan 100, Utrecht 3584 CX, The Netherlands
| | - H Issa
- Department of Pediatrics, University Hospital Frankfurt,
Goethe-University Frankfurt, Frankfurt (Main), Germany
| | - H Blair
- Wolfson Childhood Cancer Research Centre, Newcastle University,
Newcastle upon Tyne, United Kingdom
| | - R Schiffelers
- Clinical Chemistry and Haematology, University Medical Center Utrecht,
Heidelberglaan 100, Utrecht 3584 CX, The Netherlands
| | - O Heidenreich
- Princess Maxima Centrum for Pediatric Oncology, Utrecht, The
Netherlands
- Wolfson Childhood Cancer Research Centre, Newcastle University,
Newcastle upon Tyne, United Kingdom
| |
Collapse
|
6
|
Swart LE, Koekman CA, Seinen CW, Issa H, Rasouli M, Schiffelers RM, Heidenreich O. A robust post-insertion method for the preparation of targeted siRNA LNPs. Int J Pharm 2022; 620:121741. [PMID: 35421533 DOI: 10.1016/j.ijpharm.2022.121741] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 04/07/2022] [Accepted: 04/08/2022] [Indexed: 10/18/2022]
Abstract
Targeted delivery of nucleic acids is gaining momentum due to improved efficacy, selectivity, increased circulation time and enhanced tissue retention in target cells. Using nucleic acid-based therapies previously undruggable targets have proven now to be amenable for treatment. Currently, several methods for preparing targeted or labelled delivery vehicles for nucleic acids are based on liposomal formulations. Lipid nanoparticles (LNPs) are structurally different from liposomes and these methods should therefore be evaluated before being translated to siRNA LNPs preparation protocols. Here, we describe a robust and facile method for the preparation of targeted or fluorescently labelled siRNA LNPs. Using a copper free strain-promoted azide-alkyne cycloaddition (SPAAC) we demonstrate that post-insertion of ligand-lipid conjugates into preformed LNPs is superior to direct-surface modification because it preserves the physicochemical parameters of the LNPs. We found that the time point of solvent removal by dialysis is critical and affects the hydrodynamic diameter of the LNPs; post-insertion after dialysis shows the smallest increase in hydrodynamic diameter and polydispersity index (PDI). The post-insertion of ligand-lipid conjugates also proceeded with rapid kinetics and high efficacy over a wide temperature range. Using this optimised protocol, we generated siRNA LNPs containing both targeting and fluorescent tracking ligands allowing us to monitor siRNA LNP uptake kinetics in dependence of the targeting ligand. In aggregate, we describe a robust approach for the generation of targeted and labelled siRNA LNPs that allows their controlled and facile decoration with ligand combinations.
Collapse
Affiliation(s)
- L E Swart
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - C A Koekman
- Clinical Chemistry and Haematology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands
| | - C W Seinen
- Clinical Chemistry and Haematology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands
| | - H Issa
- Department of Pediatrics, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt (Main), Germany
| | - M Rasouli
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - R M Schiffelers
- Clinical Chemistry and Haematology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands
| | - O Heidenreich
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne, UK.
| |
Collapse
|
7
|
Huisjes R, Satchwell TJ, Verhagen LP, Schiffelers RM, van Solinge WW, Toye AM, van Wijk R. Quantitative measurement of red cell surface protein expression reveals new biomarkers for hereditary spherocytosis. Int J Lab Hematol 2018; 40:e74-e77. [PMID: 29746727 DOI: 10.1111/ijlh.12841] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R Huisjes
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - T J Satchwell
- School of Biochemistry, University of Bristol, Bristol, UK.,National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Blood Cell Products, University of Bristol, Bristol, UK
| | - L P Verhagen
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - R M Schiffelers
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - W W van Solinge
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - A M Toye
- School of Biochemistry, University of Bristol, Bristol, UK.,National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Red Blood Cell Products, University of Bristol, Bristol, UK
| | - R van Wijk
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
8
|
Mol E, Lei Z, Bakker MH, Vader P, Schiffelers RM, Dankers PYW, Chamuleau SAJ, Doevendans PA, Goumans MJ, Sluijter JP. 202Slow release of cardiac progenitor cell-derived extracellular vesicles from a pH-switchable hydrogel. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E Mol
- University Medical Center Utrecht, Experimental Cardiology, Utrecht, Netherlands
| | - Z Lei
- University Medical Center Utrecht, Experimental Cardiology, Utrecht, Netherlands
| | - M H Bakker
- Eindhoven University of Technology, Institute for Complex Molecular Systems, Eindhoven, Netherlands
| | - P Vader
- University Medical Center Utrecht, Experimental Cardiology and Laboratory of Clinical Chemistry and Haematology, Utrecht, Netherlands
| | - R M Schiffelers
- University Medical Center Utrecht, Laboratory of Clinical Chemistry and Haematology, Utrecht, Netherlands
| | - PYW Dankers
- Eindhoven University of Technology, Institute for Complex Molecular Systems, Eindhoven, Netherlands
| | - SAJ Chamuleau
- University Medical Center Utrecht, Experimental Cardiology, Utrecht, Netherlands
| | - P A Doevendans
- University Medical Center Utrecht, Experimental Cardiology, Utrecht, Netherlands
| | - M J Goumans
- Leiden University Medical Center, Molecular Cell Biology, Leiden, Netherlands
| | - J P Sluijter
- University Medical Center Utrecht, Experimental Cardiology, Utrecht, Netherlands
| |
Collapse
|
9
|
van der Meel R, Krawczyk-Durka M, van Solinge WW, Schiffelers RM. Toward routine detection of extracellular vesicles in clinical samples. Int J Lab Hematol 2014; 36:244-53. [PMID: 24750670 DOI: 10.1111/ijlh.12247] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 03/25/2014] [Indexed: 01/01/2023]
Abstract
The majority, if not all, of human cell types secrete extracellular vesicles (EVs) into their environment, at least partly as a means of intercellular communication. These secreted vesicles can be detected in most bodily fluids including blood, urine, and saliva. The number of secreted vesicles and their composition is altered in various pathological conditions, raising opportunities to exploit EVs as diagnostic and/or prognostic biomarkers. For this to become a reality, it is important to reach consensus regarding the standardization of protocols for sample collection, EV isolation, handling, and storage for valid comparison and interpretation of measurements. Depending on the information required, there are several detection options including EV number and size distribution, molecular surface markers, procoagulation activity, and RNA content. For these purposes, different techniques are currently utilized or under development. This review discusses the techniques that have the potential to become standard EV detection methods in a clinical diagnostic setting. In addition to the accuracy of the detection technique, other factors such as high-throughput, cost-effectiveness, time consumption, and required operator skill are important to consider. A combination of increasing fundamental knowledge, technological progress, standardization of sample collection, and processing protocols is required for EVs to become reliable predictors of altered physiology or development of disease suitable for routine clinical diagnostics. Cancer and (cardio)vascular disorders are examples of pathologies where EV detection may be applied in the near future for diagnosis and/or prognosis.
Collapse
Affiliation(s)
- R van der Meel
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | | | | |
Collapse
|
10
|
Vader P, van der Aa LJ, Storm G, Schiffelers RM, Engbersen JFJ. Polymeric carrier systems for siRNA delivery. Curr Top Med Chem 2012; 12:108-19. [PMID: 22196278 DOI: 10.2174/156802612798919123] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Revised: 08/12/2010] [Accepted: 08/14/2010] [Indexed: 11/22/2022]
Abstract
RNA interference is a technique to induce sequence-specific gene silencing, but is hampered by inefficient delivery of its mediator, short interfering RNA, into target cells. This review describes recent advances in siRNA delivery using polymeric carrier systems. Structural variations that have been applied to these polymers for optimizing their intracellular trafficking are discussed, as well as strategies for stabilization and targeting to diseased tissues in vivo. Recent findings have highlighted safety issues that need to be taken into account in the design of nanoparticles for clinical application.
Collapse
Affiliation(s)
- P Vader
- Division of Pharmaceutics, Utrecht Inistitute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
11
|
Vader P, Crielaard BJ, van Dommelen SM, van der Meel R, Storm G, Schiffelers RM. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. J Control Release 2011; 160:211-6. [PMID: 21983283 DOI: 10.1016/j.jconrel.2011.09.080] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 09/07/2011] [Accepted: 09/10/2011] [Indexed: 12/27/2022]
Abstract
Angiogenesis is an attractive target for cancer therapy, due to its central position in tumor growth and development. Vascular Endothelial Growth Factor (VEGF) and its receptors (VEGFRs) play a key role in the angiogenic process. A promising strategy for targeting VEGF-mediated angiogenesis is RNA interference (RNAi) using short interfering RNA (siRNA). However, for efficacious RNAi a well-designed siRNA delivery system is crucial. Liposome-Polycation-DNA (LPD) particles form a promising system for siRNA delivery to tumors. In order to target angiogenic endothelial cells, LPD particles may be modified with a targeting ligand, such as a cyclic Arg-Gly-Asp (RGD) peptide that specifically binds to integrins expressed on tumor-associated endothelial cells. In the current study, RGD-targeted PEGylated LPD particles containing VEGFR-2 siRNA were prepared and optimized with respect to their size and charge by varying protamine content, carrier DNA content for stronger complexation, and PEGylation density. The size of the optimized particles was around 200 nm and the ζ-potential was approximately +20 mV. The uptake and silencing efficacy of the RGD-targeted PEGylated LPD particles were evaluated in H5V cells (murine endothelial cells) and Human Umbilical Vein Endothelial cells (HUVECs). When compared to non-targeted LPD particles, enhanced uptake and silencing of VEGFR-2 expression was observed for RGD-targeted PEGylated LPD particles. In conclusion, the RGD-targeted PEGylated LPD particles containing VEGFR-2 siRNA presented here may be a promising approach for targeting VEGF-mediated angiogenesis in cancer therapy.
Collapse
Affiliation(s)
- P Vader
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
| | | | | | | | | | | |
Collapse
|
12
|
van der Aa LJ, Vader P, Storm G, Schiffelers RM, Engbersen JFJ. Optimization of poly(amido amine)s as vectors for siRNA delivery. J Control Release 2010; 150:177-86. [PMID: 21130817 DOI: 10.1016/j.jconrel.2010.11.030] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Accepted: 11/28/2010] [Indexed: 10/18/2022]
Abstract
By Michael addition polymerization of N,N'-cystaminebisacrylamide (CBA) with variable ratios of 4-amino-1-butanol (ABOL) and ethylene diamine (EDA) or triethylenetetramine (TETA), poly(amido amine) copolymers could be obtained with tunable charge densities. The copolymers were optimized to serve as nonviral vectors in RNA interference (RNAi) to form stable, nanosized polyplexes with siRNA with maximum transfection efficacy. It was observed that at least 20-30% EDA or TETA amino units in the copolymers is necessary to encapsulate siRNA into small and stable polyplexes (< 200 nm). Incorporation of higher amounts of EDA or TETA in the copolymers did not further improve polyplex formation and stability, but the increased cationic charge in these copolymers resulted in increased cytotoxicity and hemolytic activity. Copolymers with 20% EDA showed excellent gene silencing properties in vitro (70% luciferase knockdown in H1299 cells) with negligible cytotoxicity.
Collapse
Affiliation(s)
- L J van der Aa
- Department of Biomedical Chemistry, Faculty of Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands
| | | | | | | | | |
Collapse
|
13
|
van der Aa LJ, Vader P, Schiffelers RM, Engbersen JFJ. Poly(amido amine) copolymers derived from aminobutanol and ethylene diamine are excellent carriers for siRNA delivery. J Control Release 2010; 148:e85-6. [PMID: 21529647 DOI: 10.1016/j.jconrel.2010.07.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- L J van der Aa
- MIRA Institute for Biomedical Technology and Technical Medicine, Department of Biomedical Chemistry, Faculty of Science and Technology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands.
| | | | | | | |
Collapse
|
14
|
van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PMP, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9:748-60. [PMID: 19754359 DOI: 10.2174/156800909789271495] [Citation(s) in RCA: 141] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Both the epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) can contribute to tumor development and -progression through their effects on cell proliferation, inhibition of apoptosis, angiogenesis, anchorage-independent growth and tumor-associated inflammation. EGFR-targeting monoclonal antibodies and small molecule tyrosine kinase inhibitors are currently in clinical use for the treatment of several types of cancer. However, primary and acquired resistance to these agents often occurs and thereby limits the clinical efficacy of mono-specific targeted therapy. Results from both in vitro and in vivo studies indicate that cross-talk between EGFR and IGF-1R can lead to acquired resistance against EGFR-targeted drugs. This review describes the interface between the EGFR and IGF-1R signaling networks and the implications of the extensive cross-talk between these two receptor systems for cancer therapy. EGFR and IGF-1R interact on multiple levels, either through a direct association between the two receptors, by mediating the availability of each others ligands, or indirectly, via common interaction partners such as G protein coupled receptors (GPCR) or downstream signaling molecules. This multi-layered cross-talk and its involvement in the induction of resistance to targeted therapies provide a clear rationale for dual targeting of EGFR and IGF-1R. We discuss several (potential) strategies to simultaneously inhibit EGFR and IGF-1R signaling as promising novel therapeutic approaches.
Collapse
Affiliation(s)
- J van der Veeken
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
Peptides with the RGD amino acid sequence show affinity for the alpha(v)beta(3) integrin, an integrin which is over-expressed on angiogenic endothelium and involved in cell adhesion. A peptide with the sequence ATWLPPR has been demonstrated to show affinity for the vascular endothelial growth factor (VEGF) receptor, a receptor involved in the proliferation of endothelial cells. By coupling these peptides to liposomes, these liposomes can serve as a site-specific drug delivery system to tumor endothelial cells in order to inhibit angiogenesis. In the present study we demonstrate that the coupling of cyclic RGD-peptides or ATWLPPR-peptides to the surface of PEG-liposomes results in binding of these liposomes to endothelial cells in vitro. Subsequent studies with RGD-peptide targeted liposomes in vivo also demonstrate specific binding to the tumor endothelium.
Collapse
Affiliation(s)
- A P C A Janssen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Liposome-encapsulated amikacin has recently entered clinical trials. The rationale for liposome encapsulation of aminoglycosides is the possibility to increase the therapeutic index of this class of antibiotics by increasing aminoglycoside concentrations at the site of infection and/or by reducing the toxicity of these drugs. Three approaches can be distinguished: the use of liposomes as a depot formulation for local drug administration; targeting of (relatively) short circulating conventional liposomes to the cells of the mononuclear phagocyte system (MPS) for treating intracellular bacterial infections; and targeting of long-circulating liposomes to infectious foci localized outside the MPS. This review discusses the pre-clinical and clinical data in connection with recent developments in liposome technology.
Collapse
Affiliation(s)
- R Schiffelers
- Department of Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
| | | | | |
Collapse
|
17
|
Schiffelers RM, Storm G, ten Kate MT, Stearne-Cullen LE, den Hollander JG, Verbrugh HA, Bakker-Woudenberg IA. In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. J Pharmacol Exp Ther 2001; 298:369-75. [PMID: 11408564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
Antimicrobial agents may interact synergistically. But to ensure synergy in vivo, the drugs should both be present at the site of infection at sufficiently high concentrations for an adequate period of time. Coencapsulation of the drugs in a drug carrier may ensure parallel tissue distributions. Since liposomes localize preferentially at sites of infection, this mode of drug delivery could, in addition, increase drug concentrations at the focus of infection. The therapeutic efficacy of gentamicin and ceftazidime coencapsulated into liposomes was examined by monitoring survival in a rat model of an acute unilateral pneumonia caused by antibiotic-susceptible and antibiotic-resistant Klebsiella pneumoniae strains. It is shown that administration of gentamicin in combination with ceftazidime in the free form either as single dose or as 5-day treatment resulted in an additive effect on rat survival in both models. In contrast, targeted delivery of liposome-coencapsulated gentamicin and ceftazidime resulted in a synergistic interaction of the antibiotics in both models. Consequently, liposome coencapsulation of gentamicin and ceftazidime allowed both a shorter course of treatment at lower cumulative doses compared with administration of the antibiotics in the free form to obtain complete survival of rats. Liposomal coencapsulation of synergistic antibiotics may open new perspectives in the treatment of severe infections.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
18
|
Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res 2001; 18:780-7. [PMID: 11474781 DOI: 10.1023/a:1011080211226] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To gain insight into the host factors influencing liposome localization at sites of bacterial infection. METHODS In a unilateral Klebsiella pneumoniae pneumonia rat model, capillary permeability and number of circulating leukocytes was quantified and related to the degree of liposome target localization. RESULTS Liposome localization was highest in the hemorrhagic zone of infection, a zone characterized by markedly increased capillary permeability and high bacterial numbers. Both liposome localization and capillary permeability correlated positively with severity of infection. Lung instillation of other inflammatory stimuli, such as lipopolysaccharide or 0.1 M HCl inducing increased capillary permeability, also promoted liposome localization. As liposomal target localization in leukopenic rats was similar to that in immunocompetent rats, contribution of circulating leukocytes seems limited. Intrapulmonary distribution of liposomes shows that leukocytes at the target site are involved in liposome uptake after extravasation. CONCLUSIONS Increased capillary permeability plays a crucial role in liposome localization at the infected site, whereas contribution of leukocytes is limited. These results suggest inflammatory conditions that could benefit from liposomal drug delivery. The involvement of leukocytes in liposome uptake at the target site could be important information in the selection of appropriate drugs.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam, The Netherlands.
| | | | | |
Collapse
|
19
|
Schiffelers RM. Vector research group - 15th scientific meeting. IDrugs 2001; 4:286-7. [PMID: 16025386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The 15th Journées Scientifiques of the Groupe Thematique de Recherche sur les Vecteurs provided an overview of the various aspects of drug delivery systems. Copolymers of poly(lactic acid) (PLA) and poly(epsilon-caprolactone) (PCL) could be functionalized allowing the introduction of poly(ethylene) glycol side chains and ligands. Coupling of bispecific antibodies to radioactive compounds and carbohydrates to tris-(hydroxymethyl) acrylamidomethane telomers increased cell specificity. New polyhydroxy alkanoate polymers, used to prepare nanoparticles, were discussed. Promising results of a new helper lipid in the transfection of cells, fluorinated glycerophosphoethanolamine, were discussed, as was the ability of HIV protein R fragments to condensate and deliver nucleic acids. Spontaneously lysing strains of Shigella and Escherichia were reported to stably transfect cells for periods of up to 2 months. Coupling of lipid anchors to peptides allowed display at liposome surfaces, generating antibody responses to the exposed peptide loops. Long-circulating liposomes co-encapsulating synergistically acting antibiotics, showed high therapeutic efficacy in models of drug-resistant pneumonia. A long-circulating system consisting of nanoparticles with a hydrophobic core increased delivery of lipid soluble photosensitizers to tumors. Heparin was reported to be bioavailable after oral administration by use of encapsulation into nanoparticles. This review aims to show the most promising or furthest developed drug delivery systems presented at the meeting.
Collapse
Affiliation(s)
- R M Schiffelers
- University of Utrecht, Sorbonnelaan 14-16, 3584 CA, Utrecht, The Netherlands.
| |
Collapse
|
20
|
Vermehren C, Jørgensen K, Schiffelers R, Frokjaer S. Activity of mammalian secreted phospholipase A(2) from inflammatory peritoneal fluid towards PEG-liposomes. Early indications. Int J Pharm 2001; 214:93-8. [PMID: 11282244 DOI: 10.1016/s0378-5173(00)00641-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Due to an increase in the activity of phospholipase A(2) (PLA(2)) in various inflammatory diseases, this enzyme may play a key role in the degradation of liposomes and the subsequent release of drug when PEG-liposomes passively target inflammatory tissue. The activity of mammalian secreted phospholipase A(2) (sPLA(2)) in casein stimulated peritoneal fluid was tested toward liposomes of different compositions. Early results indicate only a slight degradation of conventional dipalmitoylphosphatidylcholine (DPPC) liposomes as well as DPPC liposomes incorporated with different concentrations of PEG(2000). However, the DPPC degradation increased to 7% when inclusion of 30 mol% phosphatidylethanolamine (PE) in the lipid bilayer. The increase in degradation may be due to an improvement of the substrate - as it is well known, that PE is a better substrate for the mammalian sPLA(2) than PC. Incorporation of PE into the bilayer may increase the binding properties of the bilayer resulting in improved conditions for the enzymatic attack by sPLA(2). In addition, inhibitory zones of Staphylococcus aureus in an agar diffusion test showed that PLA(2) from Crotalus atrox venom was able to catalyze the release of gentamicin from PEG-liposomes. In conclusion, this study suggest that degradation of the lipid bilayer of PEG-liposomes by PLA(2) result in release of incapsulated drug, e.g. gentamicin and inclusion of PE in the liposomal bilayer, may enhance the activity of the mammalian sPLA(2) toward liposomes composed of DPPC.
Collapse
Affiliation(s)
- C Vermehren
- Department of Pharmaceutics, The Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
| | | | | | | |
Collapse
|
21
|
Abstract
Sterically stabilized liposomes are able to localize selectively at sites of infection, potentially permitting targeted drug delivery. Up to now, the majority of studies investigating therapeutic efficacy of liposomes have been conducted in animals with an intact host defense infected with high antibiotic-susceptible bacteria. In the present study, the therapeutic efficacy of gentamicin encapsulated in sterically stabilized liposomes, alone or in combination with the free drug was studied in rats with intact host defense as well as leukopenic rats. Rats were inoculated with a high gentamicin-susceptible or low-gentamicin susceptible Klebsiella pneumoniae in the left lung, resulting in an acute unilateral pneumonia. Survival rates demonstrate the valuable therapeutic properties of the liposome-encapsulated drug in these clinically relevant animal models.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
| | | | | |
Collapse
|
22
|
Schiffelers RM, Storm G, ten Kate MT, Bakker-Woudenberg IA. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin. Antimicrob Agents Chemother 2001; 45:464-70. [PMID: 11158742 PMCID: PMC90314 DOI: 10.1128/aac.45.2.464-470.2001] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Long-circulating liposomes (LCL) may be used as targeted antimicrobial drug carriers as they localize at sites of infection. As a result, LCL-encapsulated gentamicin (LE-GEN) has demonstrated superior antibacterial activity over the free drug in a single-dose study of immunocompetent rats with Klebsiella pneumoniae pneumonia. In the present study, the therapeutic efficacy of LE-GEN was evaluated by monitoring rat survival and bacterial counts in blood and lung tissue in clinically relevant models, addressing the issue of impaired host defense and low bacterial antibiotic susceptibility. The results show that in immunocompetent rats infected with the high-GEN-susceptibility K. pneumoniae strain, a single dose of LE-GEN is clearly superior to an equivalent dose of free GEN. Yet complete survival can also be obtained with multiple doses of free GEN. In leukopenic rats infected with the high-GEN-susceptible K. pneumoniae strain, free GEN at the maximum tolerated dose (MTD) was needed to obtain survival. However, with the addition of a single dose of LE-GEN to free-GEN treatment, complete survival can be obtained using a sevenfold-lower cumulative amount of GEN than with free-GEN treatment alone. In leukopenic rats infected with low-GEN-susceptible K. pneumoniae cells, free GEN at the MTD did not result in survival. The use of LE-GEN is needed for therapeutic success. Increasing LE-GEN bilayer fluidity resulted in an increased GEN release from the liposomes and hence improved rat survival, thus showing the importance of the liposome lipid composition for therapeutic efficacy. These results warrant further clinical studies of liposomal formulations of aminoglycosides in immunocompromised patients with severe infections.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Medical Microbiology & Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | | | | | | |
Collapse
|
23
|
Schiffelers RM, Bakker-Woudenberg IA, Storm G. Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochim Biophys Acta 2000; 1468:253-61. [PMID: 11018669 DOI: 10.1016/s0005-2736(00)00265-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Preferential localization of liposomes at sites of infection or inflammation has been demonstrated in a variety of experimental models. Most studies report enhanced localization at the target site of poly(ethyelene) glycol (PEG)-coated liposomes as compared to conventional non-coated liposomes. It is generally accepted that the prolonged circulation time of PEG-coated liposomes increases target site exposure, which results in increased target localization. A quantitative relationship between circulation kinetics and localization at the pathological site has not been defined as yet. Besides, an effect of the PEG coating itself has been suggested, as theoretically the PEG coating may facilitate liposome extravasation. In the present study, in a rat model of an acute unilateral Klebsiella pneumoniae pneumonia, circulation kinetics of PEG-coated liposomes were manipulated by incorporation of different amounts of phosphatidylserine (PS) and variation of lipid dose, additionally allowing evaluation of the saturability of the localization process. In addition, this paper addresses the effect of the PEG coating, by comparing the circulation kinetics and target localization of long-circulating 'PEG-free' and PEG-coated liposomes. It is shown that the degree of liposome localization at the target site is positively linearly related to the area under the blood concentration time curve (AUC) of the liposome formulations, irrespective of PEG coating. This finding is discussed in relation to the equation of Kedem and Katchalsky, which describes protein influx into sites of infection or inflammation.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands.
| | | | | |
Collapse
|
24
|
Schiffelers RM, Bakker-Woudenberg IA, Snijders SV, Storm G. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim Biophys Acta 1999; 1421:329-39. [PMID: 10518702 DOI: 10.1016/s0005-2736(99)00139-x] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Sterically stabilized liposomes are able to localize at sites of infection and could serve as carriers of antimicrobial agents. For a rational optimization of liposome localization, the blood clearance kinetics and biodistribution of liposomes differing in poly(ethylene glycol) (PEG) density, particle size, bilayer fluidity or surface charge were studied in a rat model of a unilateral pneumonia caused by Klebsiella pneumoniae. It is shown that all liposome preparations studied localize preferentially in the infected lung compared to the contralateral non-infected lung. A reduction of the PEG density or rise in particle size resulted in a higher uptake by the mononuclear phagocyte system, lower blood circulation time and lower infected lung localization. Differences in bilayer fluidity did not affect blood clearance kinetics or localization in the infected lung. Increasing the amount of negatively charged phospholipids in the liposome bilayer did not affect blood clearance kinetics, but did reduce localization of this liposome preparation at the site of lung infection. In conclusion, the degree of localization at the infected site is remarkably independent of the physicochemical characteristics of the PEG liposomes. Substantial selective liposome localization can be achieved provided that certain criteria regarding PEG density, size and inclusion of charged phospholipids are met. These properties seem to be a direct consequence of the presence of the polymer coating operating as a repulsive steric barrier opposing interactions with biological components.
Collapse
Affiliation(s)
- R M Schiffelers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, P.O. Box 80082, 3508 TB, Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
25
|
Benson GM, Schiffelers R, Nicols C, Latcham J, Vidgeon-Hart M, Toseland CD, Suckling KE, Groot PH. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice. Atherosclerosis 1998; 141:237-47. [PMID: 9862172 DOI: 10.1016/s0021-9150(98)00177-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Although numerous transgenic mouse models for atherosclerosis have been developed recently, little is known about their response to hypolipidaemic or anti-atherosclerotic agents. We investigated the effect of the known hypocholesterolaemic and anti-atherosclerotic drug probucol on serum lipids, lipoproteins and atherosclerosis in fat-fed low density lipoprotein (LDL) receptor deficient mice. Probucol at doses of 0.2 and 1% in the diet which are similar to those used in the mouse by other investigators reduced serum cholesterol by 26 and 37%, respectively. Probucol also reduced serum triglyceride levels by 33 and 47% at doses of 0.2 and 1%, respectively. The decrease in serum cholesterol and triglycerides was mainly due to a decrease of these lipids in VLDL and or chylomicrons. Despite these potentially beneficial changes in serum lipids atherosclerotic lesion areas in the aortic root were unchanged in the probucol treated mice. After 12 weeks treatment most of the mice receiving probucol had swollen feet and tails due to oedema. Histological examination of the base of the hearts from the probucol treated mice revealed lipid droplets within the reticuloendothelial and other interstitial cells. There was also an interstitial subacute inflammatory cell infiltration associated with the lipid deposition. The oedema induced by probucol could be the result of cardiac insufficiency due to interstitial lipidosis and inflammation in the base of the heart together with the extensive atherosclerotic lesions in the aortic sinus.
Collapse
Affiliation(s)
- G M Benson
- Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, NFSP(North), Harlow, Essex, UK.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Rensen PC, Schiffelers RM, Versluis AJ, Bijsterbosch MK, Van Kuijk-Meuwissen ME, Van Berkel TJ. Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol 1997; 52:445-55. [PMID: 9281607 DOI: 10.1124/mol.52.3.445] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Progressive hypocholesterolemia is a feature associated with a number of cancers of different origin, and it is caused by the high expression of low-density lipoprotein (LDL) receptors (LDLrs) on many tumor cell types. Selective delivery of chemotherapeutics using LDL as a carrier has therefore been proposed, but the endogenous nature of LDL hampers its pharmaceutical application. In the current study, we explored the possibility of synthesizing liposomes that mimic LDL from commercially available lipids and proteins. Small unilamellar liposomes were created (28.9 +/- 0.9 nm) and complexed with 5.8 +/- 0.7 molecules of human recombinant apolipoprotein E (apoE). On intravenous injection into rats, the liposomes retained their aqueous core, structural integrity, and the majority of the preassociated apoE. [3H]Cholesteryl oleate-labeled apoE-enriched liposomes showed a relatively long serum half-life (>5 hr), and a low uptake by cells of the reticuloendothelial system was observed (<0.8% of the injected dose at 30 min after injection). Pretreatment of rats with 17alpha-ethinyl estradiol, which induces the expression of the LDLr on the liver and adrenals, led to a 2.5-fold accelerated serum clearance (t1/2 = 123 +/- 10 min) and a selectively increased uptake of liposomes by the liver (2.0-fold) and adrenals (3.8-fold). The liver association of the liposomes was coupled to the lysosomal uptake route, similarly as for LDL. In vitro studies using B16 melanoma cells showed that the liposomes bound exclusively to the LDLr via their apoE moiety (90,000 liposomes/cell), with a 14-fold higher affinity (Kd = 0.77 +/- 0.09 nM) than LDL itself. Because of their favorable properties, we anticipate that these apoE-enriched liposomes are advantageous compared with native LDL in the development of a selective LDLr-targeted antitumor therapy.
Collapse
Affiliation(s)
- P C Rensen
- Division of Biopharmaceutics, Leiden-Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands.
| | | | | | | | | | | |
Collapse
|
27
|
Groot PH, van Vlijmen BJ, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, Havekes LM. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996; 16:926-33. [PMID: 8696955 DOI: 10.1161/01.atv.16.8.926] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Transgenic mice overexpressing the human dysfunctional apolipoprotein E variant, APOE*3 Leiden, develop hyperlipidemia and are highly susceptible to diet-induced atherosclerosis. In the present study, we investigated the effects of diet composition and feeding period on serum cholesterol exposure and the amount of atherosclerosis in the aortic sinus in these mice, using quantitative image analysis. On each of the three diets tested--a low-fat diet, a high-saturated-fat/cholesterol diet, and a high saturated-fat/high-cholesterol/0.5%-cholate diet--transgenic animals showed a marked hyperlipidemia compared with nontransgenic littermates. Measurement of the atherosclerotic lesion areas in cross sections of the aortic sinus in animals exposed to these three diets for up to 6 months showed a 5 to 10 times greater lesion area in transgenic mice compared with nontransgenic controls. Highly significant positive correlations were found between the log-transformed data on lesion area and serum cholesterol exposure (r = .82 to .85 for the 1-, 2-, and 3-month treatment groups), indicating that the hyperlipidemia is likely to be a major determinant in lesion formation. On the basis of these findings, we suggest that the APOE*3 Leiden mouse represents a promising model for intervention studies with hypolipidemic and antiatherosclerotic drugs.
Collapse
Affiliation(s)
- P H Groot
- Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Welwyn, Hertfordshire, UK. @inet
| | | | | | | | | | | | | |
Collapse
|